Page 76 - Read Online

Page 8 of 10 Yilmaz et al. Hepatoma Res 2018;4:46 I http://dx.doi.org/10.20517/2394-5079.2018.49

Authors’ contributions
Design: Yilmaz N
Literature review: Yilmaz N, Suer K, Goral V, Cakir N
Manuscript writing: Yilmaz N
Manuscript review and editing: Yilmaz UE
Approved the final article: all authors

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in
2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. [Last accessed on 10 Aug 2018]
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol
2018;69:182-236.
3. El-Serag H, Kanwal H. Epidemiology of hepatocellular carcinoma in the United States: where are we? where do we go? Hepatology
2014;60:1767-75.
4. Torre LA, Siegel RL, Ward EM, Jem A. Global cancer incidence and mortality rates and trends--an update. Cancer Epidemiol Biomarkers
Prev 2016;25:16-27.
5. Altekruse SF, McGlynn KA, Reichman MA. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from
1975 to 2005. J Clin Oncol 2009;27:1485-91.
6. Sheldon WH, James DF. Cirrhosis following infectious hepatitis; a report of five cases, in two of which there was superimposed primary
liver cell carcinoma. Arch Intern Med (Chic) 1948;81:666-89.
7. Nikulina D, Terentyev A, Galimzyanov K, Jurišić V. Fifty years of discovery of alpha-fetoprotein as the first tumor marker. Srp Arh Celok
Lek 2015;143:100-4.
8. Tang ZY. Screening and early treatment of primary liver cancer--with special reference to the east part of China. Ann Acad Med 1980;9:234-
9.
9. Altekruse SF, Henley SJ, Cucinelli JE, Mc Glynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the
United States. Am J Gastroenterol 2014;109:542-53.
10. Jemal A, Bray B, Center MM, Ferlay F, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
11. Global Burden of Disease Liver Cancer Collaboration; Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, Al-Raddadi
R, Alvis-Guzman N, Amoako Y, Artaman A, Ayele TA, Barac A, Bensenor I, Berhane A, Bhutta Z, Castillo-Rivas J, Chitheer A, Choi JY,
Cowie B, Dandona L, Dandona R, Dey S, Dicker D, Phuc H, Ekwueme DU, Zaki MS, Fischer F, Fürst T, Hancock J, Hay SI, Hotez P,
Jee SH, Kasaeian A, Khader Y, Khang YH, Kumar A, Kutz M, Larson H, Lopez A, Lunevicius R, Malekzadeh R, McAlinden C, Meier
T, Mendoza W, Mokdad A, Moradi-Lakeh M, Nagel G, Nguyen Q, Nguyen G, Ogbo F, Patton G, Pereira DM, Pourmalek F, Qorbani
M, Radfar A, Roshandel G, Salomon JA, Sanabria J, Sartorius B, Satpathy M, Sawhney M, Sepanlou S, Shackelford K, Shore H, Sun J,
Mengistu DT, Topór-Mądry R, Tran B, Ukwaja, Vlassov V, Vollset SE, Vos T, Wakayo T, Weiderpass E, Werdecker A, Yonemoto N, Younis
M, Yu C, Zaidi Z, Zhu L, Murray CJL, Naghavi M, Fitzmaurice C. The burden of primary liver cancer and underlying etiologies from 1990
to 2015 at the global, regional, and national level. JAMA Oncol 2017;3:1683-91.
12. Wong GL, Wong VW, Tan GM, Ip KI, Lai WK, Li YW, Mak MS, Lai PB, Sung JJ, Chan HL. Surveillance programme for hepatocellular
carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int 2008;28:79-87.
13. Wong GL. Optimal surveillance program for hepatocellular carcinoma - getting ready, but not yet. World J Hepatol 2015;7:2133-5.